BenevolentAI Investor Day Presentation Deck

Internal validation: pipeline generated from the Benevolent Platform™ BEN-2293 | Atopic Dermatitis BEN-8744 | Ulcerative Colitis BEN-9160 | Amyotrophic Lateral Sclerosis BEN-28010 | Glioblastoma Multiforme Inflammatory Bowel Disease Amyotrophic Lateral Sclerosis Antiviral Oncology Oncology Nonalcoholic Steatohepatitis Oncology Parkinson's Disease Parkinson's Disease Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis +10 Exploratory stage programmes Target ID Hit to Lead Lead Opt AstraZeneca AstraZeneca AstraZeneca Preclinical Phase I Phase II Phase III Highlights • All Pipeline programmes generated from the Benevolent Platform™ • Broad therapy area coverage given disease-agnostic approach to date, with future investment to focus on three Therapeutic Indications ● 50/50 mix of Best in class and novel / First in Class indications • Potential for rapid scaling and expansion into new modalities Benevolent 41

View entire presentation